Table 5.
Adjusted Vaccine Effectiveness for Vaccine Status Groups at Least 1 Dose of Vaccine at 9–14 and Complete Series On-schedule at 9–14 Years of Age Versus Unvaccinated
| Vaccine Status | n | HSIL | CIN2 | CIN3 | CIN 2+ | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Cases | Average Follow-up y ± SD | Adjusted VE, % (95% CI) | No. of Cases | Average Follow-up y ± SD | Adjusted VE, % (95% CI) | No. of Cases | Average Follow-up y ± SD | Adjusted VE, % (95% CI) | No. of Cases | Average Follow-up y ± SD | Adjusted VE, % (95% CI) | ||
| Unvaccinated | 14 130 | 229 | 5.5 ± 2.1 | Ref | 55 | 6.8 ± 2.1 | Ref | 60 | 6.8 ± 2.1 | Ref | 115 | 6.8 ± 2.1 | Ref |
| At least 1 dose 9–14 y | 20 738 | 191 | 5.7 ± 2.1 | 46.4 (35.0–55.9) | 51 | 7.1 ± 2.1 | 38.7 (0.00–58.3) | 25 | 7.1 ± 2.1 | 72.7 (57.0–83.2) | 76 | 7.1 ± 2.1 | 56.6 (42.0–67.7) |
| Complete series on schedule 9–14 y | 18 975 | 171 | 5.7 ± 2.1 | 47.1 (35.6–56.7) | 45 | 7.0 ± 2.1 | 40.6 (0.00–60.1) | 22 | 7.0 ± 2.1 | 73.6 (57.5–84.1) | 67 | 7.0 ± 2.1 | 57.9 (43.2–69.0) |
| At least 1 dose 15+ y | 3436 | 68 | 6.2 ± 2.2 | 1.2 (0.00–25.3) | 14 | 7.5 ± 2.2 | 18.4 (0.00–56.5) | 12 | 7.5 ± 2.2 | 32.0 (0.00–65.3) | 26 | 7.5 ± 2.2 | 25.3 (0.00–52.4) |
| Complete series on schedule 15+ y | 1997 | 32 | 6.2 ± 2.2 | 20.3 (0.00–46.0) | 8 | 7.5 ± 2.2 | 20.8 (0.00–65.2) | 5 | 7.5 ± 2.2 | 52.1 (0.00–83.3) | 13 | 7.5 ± 2.2 | 36.8 (0.00–66.1) |
Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; VE, vaccine effectiveness.